Publications by authors named "Ina Rudolph"
Despite the introduction of JAK inhibitors, allogeneic hematopoietic cell transplant remains the only potentially curative treatment for patients with myelofibrosis but has considerable treatment-related complications. Whether the incorporation of JAK inhibition into the transplant algorithm leads to improved outcomes is still unclear. Here, we analyzed different transplant platforms in myelofibrosis patients undergoing a first transplant, comparing immune profiles and outcomes of (1) 33 patients continuing JAK inhibition at start of conditioning until stable engraftment (PERI-group), (2) 38 patients receiving JAK inhibition prior to transplant until start of conditioning (PRE-group), and (3) 38 patients that had never received JAK inhibition (NON-group).
View Article and Find Full Text PDFArticle Synopsis
- The optimal TBI dose for patients with high-risk acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation (SCT) is still uncertain.
- A retrospective analysis compared outcomes of patients treated with 8 Gy and 12 Gy total body irradiation (TBI) along with fludarabine and PTCy, revealing that while both doses show similar overall and leukemia-free survival, the 12 Gy dose offers better outcomes for MRD-positive patients.
- The study suggests that the 8 Gy TBI results in lower non-relapse mortality but a higher relapse rate compared to 12 Gy, highlighting the need for further research to confirm these results with larger MRD patient groups.
We retrospectively analyzed high-risk ALL patients in CR1 receiving total body irradiation based conditioning regimen with ATLG (n = 74) or PTCy (n = 73) for GVHD prophylaxis. The 3-year OS and LFS were similar in both groups: 65 and 60% in the ATLG group and 64 and 67% in the PTCy group (p = 0.9 and 0.
View Article and Find Full Text PDFBackground: Schizophrenia is a severe mental illness associated with hallucinations, delusions, apathy, poor social functioning, and impaired cognition. Researchers and funders have been hesitant to focus efforts on treatment preferences of patients with schizophrenia because of the perceived cognitive burden that research methods, such as conjoint analysis, place on them.
Objective: The objective of this study was to test if patients diagnosed with schizophrenia were able to complete a choice-based conjoint analysis (often referred to as discrete-choice experiments) and to test if meaningful trade-offs were being made.
[Objectivity in research in the pharmaceutical industry is possible].
Z Evid Fortbild Qual Gesundhwes
August 2010
A number of publications on publication bias or selected outcomes reporting have led critics to doubt that the pharmaceutical industry is able to remain objective in its research activities. This paper discusses the prerequisites for objective research and to what extent these are met by research projects conducted by the pharmaceutical industry. Problems with meeting objectivity criteria on the part of the pharmaceutical industry will be highlighted, distinguishing between industrial research activities themselves (i.
View Article and Find Full Text PDFArticle Synopsis
- The study highlights the importance of measuring patient preferences in ADHD treatment, emphasizing the need for their values to be considered in healthcare decisions.
- Through Discrete Choice Experiments (DCE), researchers identified significant factors that patients prioritize, such as improvements in social and emotional well-being and the effectiveness of medication throughout the day.
- The findings suggest that addressing these preferences can enhance patient-centered care and better align treatments with the needs of individuals with ADHD.
Objectives: Schizophrenia imposes a great burden on society, and while evaluation should play an important role in informing society's efforts to alleviate these burdens, it is unclear what "endpoints" should be chosen as the objective of such analyses. The objectives of the study were to elicit endpoints directly from patients with schizophrenia, to ascertain whether patients are sufficiently cognoscente to express what endpoints are and are not important to them and to rank the relevant endpoints.
Methods: We applied principles of patient-centered health technology assessment to identify and value endpoints from the patient's perspective.